Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins

Highly expressed recombinant human follicle-stimulating hormone from Chinese hamster ovary cells grown in serum-free medium and its effect on induction of folliculogenesis and ovulation

“…Additionally, 5/5 IU Follimon treatment increased the number of oocytes collected compared with 10/10 IU Follimon treatment, but the differences between the two groups were not significant. Recently, studies comparing rFSH and urinary FSH in trials dealing with superovulation induction for IVF have reported that a significantly lower total dose of rFSH was needed to yield a better ovarian response with a higher number of retrieved oocytes and a higher number of embryos obtained in IVF (25)(26)(27). However, other studies reported that there are no statistically significant differences in mean number of oocytes, clinical pregnancy rate, or live birth rate between highly purified urinary FSH and recombinant FSH (28,29) and that there is a significant increase in number of oocytes with use of urinary menopausal gonadotropin (MG) or FSH compared with rFSH (30,31).…”

La fécondation in vitro en France. Approche économique et influence du choix des gonadotrophines (urinaires ou recombinantes) sur le coût

“…Dans cette étude, le prix de la u-FSH était de 58 % inférieur au prix de la r-FSH. L'auteur avait pris comme différence entre r-FSH et u-FSH, les résultats d'une méta-analyse de 3 études [28], publiée en 1997, montrant qu'un traitement par Puregon ® permettait d'obtenir environ 25 % de grossesses en plus (soit 7 % par cycle), par rapport à un traitement par Metrodin-HP ® (Serono), différence qui n'a d'ailleurs pas été retrouvée dans les méta-analyses suivantes. Les auteurs ont effectué des simulations en prenant comme hypothèse une cohorte de 10 000 patientes suivies jusqu'à l'obtention d'une grossesse, avec un maximum de trois cycles de stimulation, et en incluant les TEC résultant des ponctions.…”

Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation forin-vitrofertilisation: does purity improve outcome?

“…While studies comparing the different gonadotropin preparations during IVF cycles have yielded conflicting results for pregnancy rate [3][4][5], three large systematic reviews that have recently evaluated Correspondence: Raoul Orvieto, Infertility and IVF Unit, Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon 78278, Israel. Fax: þ972-8-6745134.…”